Iovance Biotherapeutics is seeing some action, up about 30% recently. They reported $68 million in revenue for the latest quarter, which is a 13% increase. The company released new data on their melanoma treatment, Amtagvi. In real-world conditions, the drug showed a 52% objective response rate. That is higher than the 31% figure seen in the clinical trials used for approval. The stock is currently trading under $3. They aren't profitable yet but are running Phase 2 trials for other indications.